Navigation Links
Bacterial toxins cause deadly heart disease
Date:8/19/2013

University of Iowa researchers have discovered what causes the lethal effects of staphylococcal infective endocarditis - a serious bacterial infection of heart valves that kills approximately 20,000 Americans each year.

According to the UI study, the culprits are superantigens -- toxins produced in large quantities by Staphylococcus aureus (staph) bacteria - which disrupt the immune system, turning it from friend to foe.

"The function of a superantigen is to 'mess' with the immune system," says Patrick Schlievert, Ph.D., UI professor and chair of microbiology at the UI Carver College of Medicine. "Our study shows that in endocarditis, a superantigen is over-activating the immune system, and the excessive immune response is actually contributing very significantly to the destructive aspects of the disease, including capillary leakage, low blood pressure, shock, fever, destruction of the heart valves, and strokes that may occur in half of patients."

Other superantigens include toxic shock syndrome toxin-1, which Schlievert identified in 1981 as the cause of toxic shock syndrome.

Staph bacteria is the most significant cause of serious infectious diseases in the United States, according to the Centers for Disease Control and Prevention (CDC), and infective endocarditis is the most serious complication of staph bloodstream infection. This dangerous condition affects approximately 40,000 people annually and has a death rate of about 50 percent. Among patients who survive the infection, approximately half will have a stroke due to the damage from the aggressive infection of the heart valves.

Despite the serious nature of this disease, little progress has been made over the past several decades in treating the deadly condition.

The new study, led Schlievert, and published Aug. 20 in the online open-access journal mBio, suggests that blocking the action of superantigens might provide a new approach for treating infective endocarditis.

"We have high affinity molecules that neutralize superantigens and we have previously shown in experimental animals that we can actually prevent strokes associated with endocarditis in animal models. Likewise, we have shown that we can vaccinate against the superantigens and prevent serious disease in animals," Schlievert says.

"The idea is that either therapeutics or vaccination might be a strategy to block the harmful effects of the superantigens, which gives us the chance to do something about the most serious complications of staph infections."

The UI scientists used a strain of methicillin resistant staph aureus (MRSA), which is a common cause of endocarditis in humans, in the study. They also tested versions of the bacteria that are unable to produce superantigens. By comparing the outcomes in the animal model of infection with these various bacteria, the team proved that the lethal effects of endocarditis and sepsis are caused by the large quantities of the superantigen staphylococcal enterotoxin C (SEC) produced by the staph bacteria.

The study found that SEC contributes to disease both through disruption of the immune system, causing excessive immune response to the infection and low blood pressure, and direct toxicity to the cells lining the heart.

Low blood flow at the infection site appears to be one of the consequences of the superantigen's action. Increasing blood pressure by replacing fluids reduced the formation of so-called vegetations plaque-like meshwork made up of cellular factors from the body and bacterial cells -- on the heart valves and significantly protected the infected animals from endocarditis. The researchers speculate that increased blood flow may act to wash away the superantigen molecules or to prevent the bacteria from settling and accumulating on the heart valves.


'/>"/>

Contact: Jennifer Brown
jennifer-l-brown@uiowa.edu
319-356-7124
University of Iowa Health Care
Source:Eurekalert

Related biology news :

1. UC Davis researchers discover molecular target for the bacterial infection brucellosis
2. Newly discovered bacterial partnership changes ocean chemistry
3. Bacterial blockade
4. Study finds depletion of alveolar macrophages linked to bacterial super-infections
5. New methods to visualize bacterial cell-to-cell communication
6. UT study: Chemical in antibacterial soaps may harm nursing babies
7. Spinning up antibacterial silver on glass
8. Bacterial DNA may integrate into human genome more readily in tumor tissue
9. HIV-derived antibacterial shows promise against drug-resistant bacteria
10. Metabolic model of E. coli reveals how bacterial growth responds to temperature change
11. Bacterial security agents go rogue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
(Date:11/21/2016)...   Neurotechnology , a provider of high-precision ... that the MegaMatcher On Card fingerprint matching algorithm ... NIST Minutiae Interoperability Exchange (MINEX) III ... of the evaluation protocol. The ... fingerprint templates used to establish compliance of template ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... announce that Biohaven has issued today the following press ... (PRWEB) Dec 9, 2016 - Biohaven Pharmaceutical Holding ... the U.S. Food and Drug Administration ("FDA") has granted ... candidate BHV-0223, an orally dissolving tablet being developed for ...
(Date:12/8/2016)... -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS ... today announced financial results for the fiscal first ... on our commitment to address an unmet medical ... pleased with the early clinical response data presented ... focused on advancing our lead program – ImmunoPulse® ...
(Date:12/8/2016)... , Dec. 8, 2016 Eurofins announces the appointment ... and President of Eurofins Scientific Inc. (ESI). Mr. ... his proven professional and entrepreneurial experience in leading international business teams. ... US food testing market to uphold Eurofins, status as the global ... ...
(Date:12/8/2016)... BARCELONA, Spain , Dec. 8, 2016  Anaconda ... on the development of the next generation neuro-thrombectomy system ... the appointment of Tudor G. Jovin, MD to join ... to serve as a strategic network of scientific and ... progresses the development of the ANCD BRAIN ® ...
Breaking Biology Technology: